Corium International Inc. (CORI) Given Average Rating of “Buy” by Analysts
Shares of Corium International Inc. (NASDAQ:CORI) have received a consensus rating of “Buy” from the six brokerages that are covering the company. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $13.40.
A number of brokerages have recently commented on CORI. Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, July 19th. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Corium International in a research note on Thursday, June 23rd. Finally, FBR & Co set a $18.00 target price on Corium International and gave the stock a “buy” rating in a research note on Friday, August 5th.
A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in Corium International by 82.4% in the first quarter. State Street Corp now owns 132,615 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 59,905 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of Corium International during the second quarter worth approximately $152,000. RTW Investments LLC boosted its position in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock worth $2,960,000 after buying an additional 24,629 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Corium International by 1.4% in the first quarter. Franklin Resources Inc. now owns 818,290 shares of the biopharmaceutical company’s stock worth $3,158,000 after buying an additional 11,200 shares during the last quarter. Finally, Opaleye Management Inc. boosted its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares during the last quarter. 88.15% of the stock is owned by institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/corium-international-inc-cori-given-average-rating-of-buy-by-analysts.html
Corium International (NASDAQ:CORI) traded down 2.86% during trading on Monday, reaching $5.09. The company’s stock had a trading volume of 27,427 shares. The stock has a 50-day moving average of $5.72 and a 200 day moving average of $4.61. Corium International has a one year low of $3.14 and a one year high of $9.93. The firm’s market capitalization is $113.81 million.
Corium International (NASDAQ:CORI) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Corium International had a negative return on equity of 158.38% and a negative net margin of 104.77%. On average, equities research analysts predict that Corium International will post ($1.62) EPS for the current fiscal year.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.